Related Experiment Video
Updated: Feb 15, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Brentuximab vedotin: clinical updates and practical guidance
Jun Ho Yi1, Seok Jin Kim2, Won Seog Kim2
1Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea.
Brentuximab vedotin (BV) is an effective antibody-drug conjugate for CD30-positive lymphomas. This review details recent clinical trial updates and practical guidance for using BV in practice.
Area of Science:
- Oncology
- Pharmacology
- Immunotherapy
Background:
- Brentuximab vedotin (BV) is an antibody-drug conjugate targeting the CD30 antigen.
- BV demonstrated significant efficacy in CD30-positive lymphomas, leading to its accelerated approval in 2011.
- Subsequent large-scale trials have expanded the understanding and application of BV.
Purpose of the Study:
- To provide a comprehensive review of the latest clinical trial findings for Brentuximab vedotin.
- To offer updated, in-practice guidance for the clinical use of BV.
- To summarize the evolving role of BV in treating CD30-positive malignancies.
Main Methods:
- Systematic literature review of clinical trials involving Brentuximab vedotin.
- Analysis of data from large-scale studies and post-approval investigations.
- Synthesis of clinical evidence to inform practical usage guidelines.
Main Results:
- BV has shown remarkable efficacy in Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma.
- Numerous trials have supported the extension of BV's indications beyond its initial approval.
- Updated data confirm BV's established role and explore new therapeutic contexts.
Conclusions:
- Brentuximab vedotin remains a cornerstone therapy for CD30-positive lymphomas.
- Continuous research and clinical experience are refining the optimal use of BV.
- This review consolidates current knowledge for effective clinical application of BV.
Related Concept Videos
Characteristics of Practical Op Amps
The ratio of differential gain to the common-mode gain is defined as the common-mode rejection ratio (CMRR). This ratio quantifies the ability of operational amplifiers (op-amps) to reject common-mode...
Theoretical Foundations of Nursing Practice
Theories provide a perspective to assess patients' conditions and organize data and methods. They also assist in analyzing and interpreting information. They represent a...
Equivalent Circuits for Practical Transformers
In a practical transformer, each winding exhibits resistance and leakage reactance. The...
Nursing Clinical Information System
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview

